Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Subclones of drug-resistant hepatitis B virus mutants and the outcome of breakthrough hepatitis in patients treated with lamivudine.

Intervirology - 1 Jan 2003

Kumashiro Ryukichi, Kuwahara Reiichiro, Ide Tatsuya, Koga Yuriko, Arinaga Teruko, Hisamochi Akiko, Ogata Kei, Tanaka Kazuo, Sata Michio

Abstract excerpt

Breakthroughs during lamivudine therapy were assessed according to hepatitis flares and mutational polymorphism of hepatitis B virus (HBV) infecting patients. Of 42 patients with chronic hepatitis B and positive for hepatitis B e antigen in serum, 13 (30%) harbored HBV mutants with lamivudine res...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to DNA-Directed DNA Polymerase
Share to DNA, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to Hepatitis B

Share to Hepatitis B, Chronic

Share to Hepatitis B virus

Share to Lamivudine

Source

Identifiers

PMID: 14688451
DOI: 10.1159/000074991

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-14688451-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Subclones of drug-resistant hepatitis B virus mutants and the outcome of breakthrough hepatitis in patients treated with lamivudine.PMID 14688451Read ↗

Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance.Semantic proximity Read ↗

Characteristics of lamivudine-resistant hepatitis B virus (HBV) strains with and without breakthrough hepatitis in patients with chronic hepatitis B evaluated by serial HBV full-genome sequences.Semantic proximity Read ↗

Efficacy of alpha interferon therapy for lamivudine resistance in chronic hepatitis B.Semantic proximity Read ↗

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.Semantic proximity Read ↗

Long-term follow-up study of Chinese patients with YMDD mutations: significance of hepatitis B virus genotypes and characteristics of biochemical flares.Semantic proximity Read ↗

Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy after biochemical breakthrough of YMDD mutants.Semantic proximity Read ↗

Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis BSemantic proximity Read ↗

Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease.Semantic proximity Read ↗

Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences.Semantic proximity Read ↗

Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough.Semantic proximity Read ↗

Fatal hepatic failure after emergence of the hepatitis B virus mutant during lamivudine therapy in a patient with liver cirrhosis.Semantic proximity Read ↗

Virological and biochemical relapse according to YMDD motif mutant type during long-term lamivudine monotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.